Drug Trial Radar · NCT00376168
A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease
Last checked: Nov 20, 2026Latest source record: Oct 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Aug 2007
Primary completion
Sep 2009
Study completion Oct 2009
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Sep 14, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Gaucher disease, the most prevalent lysosomal storage disorder, is caused by mutations in the human glucocerebrosidase gene (GCD) leading to reduced activity of the lysosomal enzyme glucocerebrosidase and thereby to the accumulation of substrate glucocerebroside (GlcCer) in the cells of the monocyte-macrophage system. This is the second trial to utilize a recombinant active form of lysosomal enzyme, glucocerebrosidase, (human prGCD) which is expressed and purified in a bioreactor system from transformed carrot plant root cell line.
Conditions
- Gaucher Disease
Interventions
Plant cell expressed recombinant glucocerebrosidase (prGCD)Drug
Intravenous infusion every two weeks for 9 months
Plant cell expressed recombinant glucocerebrosidase (prGCD)Drug
Intravenous infusion every 2 weeks for 9 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Spleen Volume Measured by MRI.Time frame: Baseline and 9 months
Locations
11 sites in 8 countries. Site status is shown where the registry gives one.
University Research Foundation for Lysosomal Storage Diseases
Coral Springs, Florida
Division of Medical Genetics, Emory University School of Medicine
Decatur, Georgia
New York University Medical Center
New York, New York
Mount Sinai Hospital
Toronto, Ontario, Canada
Pontificia Universidad Catolica de Chile
Santiago, Chile
Rambam Medical Center
Haifa, Israel
Shaare Zedek Medical Center
Jerusalem, Israel
Universita "La Sapienza"
Rome, Italy
Morningside Medi-Clinic
Morningside, South Africa
Hospital Universitario Miguel Servet
Zaragoza, Spain
Royal Free Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.